Inhibitors of Lyn and Syk tyrosine kinases, which are active participants in the pre-BCR pathway, have been shown to negatively affect survival of pre-BCR+ ALL cells, thus highlighting the therapeutic potential of these small molecules in combating B-ALL [7]. This evidence concerns the gene BCR and precursor B-cell acute lymphoblastic leukemia.